Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial.
complete remission
estimated glomerular filtration rate
focal segmental glomerulosclerosis
open-label extension
proteinuria
surrogate endpoint
Journal
Kidney international reports
ISSN: 2468-0249
Titre abrégé: Kidney Int Rep
Pays: United States
ID NLM: 101684752
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
03
02
2023
revised:
12
06
2023
accepted:
24
07
2023
medline:
18
10
2023
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
epublish
Résumé
Focal segmental glomerulosclerosis (FSGS) is a rare glomerular disease with high unmet clinical need. Interest in proteinuria as a surrogate end point for regulatory approval of novel treatments has increased. We assessed the relationship between achieving complete remission (CR) of proteinuria at least once during follow-up and long-term kidney outcomes. This A total of 108 patients who received ≥1 sparsentan dose were included in this study. During a median follow-up of 47.0 months, 46 patients (43%) experienced ≥1 CR, 61% occurring within 12 months of starting sparsentan. There was an increased likelihood of CR with a higher sparsentan dose or baseline subnephrotic-range proteinuria. Achieving ≥1 CR was associated with significantly slower rate of estimated glomerular filtration rate (eGFR) decline versus non-CR patients ( We conclude that sparsentan can be safely administered for extended periods and exerts a sustained antiproteinuric effect. Achievement of CR at any time during follow-up, even if it is not sustained, may be an indicator of a favorable response to treatment and a predictor of improved kidney function outcomes.
Identifiants
pubmed: 37850006
doi: 10.1016/j.ekir.2023.07.022
pii: S2468-0249(23)01401-8
pmc: PMC10577371
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2017-2028Informations de copyright
© 2023 International Society of Nephrology. Published by Elsevier Inc.
Références
Nat Rev Nephrol. 2015 Nov;11(11):635-6
pubmed: 26324198
J Am Soc Nephrol. 2005 Apr;16(4):1061-8
pubmed: 15716334
Clin J Am Soc Nephrol. 2019 Mar 7;14(3):469-481
pubmed: 30635299
N Engl J Med. 2011 Dec 22;365(25):2398-411
pubmed: 22187987
Am J Kidney Dis. 2021 Feb;77(2):216-225
pubmed: 32791086
Ann Intern Med. 2008 Jan 1;148(1):30-48
pubmed: 17984482
Biomed Res Int. 2016;2016:3295618
pubmed: 27144163
Am J Kidney Dis. 2020 Jan;75(1):84-104
pubmed: 31473020
Nephrol Dial Transplant. 2023 Mar 31;38(4):950-960
pubmed: 35948275
Am J Physiol Regul Integr Comp Physiol. 2016 May 15;310(10):R877-84
pubmed: 27009050
Kidney Med. 2022 Jun 11;4(8):100501
pubmed: 36032548
J Am Soc Nephrol. 2019 Sep;30(9):1735-1745
pubmed: 31292197
Pediatr Nephrol. 2015 Oct;30(10):1793-802
pubmed: 25690943
J Am Soc Nephrol. 2018 Nov;29(11):2745-2754
pubmed: 30361325
Am J Kidney Dis. 2021 Sep;78(3):340-349.e1
pubmed: 33775708
J Am Soc Nephrol. 2015 Jun;26(6):1279-89
pubmed: 25349199
Front Pediatr. 2016 Mar 23;4:25
pubmed: 27047908
Expert Opin Emerg Drugs. 2020 Sep;25(3):367-375
pubmed: 32729368
Adv Chronic Kidney Dis. 2014 Sep;21(5):417-21
pubmed: 25168830
Adv Chronic Kidney Dis. 2014 Mar;21(2):194-9
pubmed: 24602468
Kidney Int Rep. 2017 Mar 04;2(4):654-664
pubmed: 29142983
Pediatr Nephrol. 2006 Mar;21(3):344-9
pubmed: 16395603
Kidney Int. 2021 Oct;100(4S):S1-S276
pubmed: 34556256
J Am Soc Nephrol. 2015 Dec;26(12):2930-7
pubmed: 26078365
Clin J Am Soc Nephrol. 2018 Mar 7;13(3):414-421
pubmed: 29167190
Clin J Am Soc Nephrol. 2017 Mar 7;12(3):502-517
pubmed: 28242845
J Am Soc Nephrol. 2012 Nov;23(11):1769-76
pubmed: 22997260